Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Pharmaceutical Executive May 1, 2006 Sarah Houlton	Global Report: A Hope and a Payer If current trends continue, the United Kingdom will spend 12.7 percent of its GDP on healthcare by 2050. Maybe that means it's time to reform the National Health Service's notoriously complex drug payment scheme.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool December 19, 2006 Brian Gorman	Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note.
Chemistry World April 2007 Richard Barker	Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago.
Chemistry World June 18, 2008 Ananyo Bhattacharya	Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service
Pharmaceutical Executive September 1, 2005 Sarah Houlton	Global Report: Kids 'R' EU After years of delay, the European Parliament is ready to vote on pediatric-testing legislation.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
Chemistry World July 29, 2015 Phillip Broadwith	Hikma boosts generics with Roxane buyout UK-headquartered Hikma Pharmaceuticals has agreed to buy Roxane Laboratories -- Boehringer Ingelheim's generic medicines unit -- for a total of $2.65 billion.
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
Pharmaceutical Executive May 1, 2005 Sarah Houlton	Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
Pharmaceutical Executive February 1, 2006 Sarah Houlton	Global Report: Moving Towards Generic Biologics The European Medicines Agency hopes to complete its guidelines for the approval of biosimilar drugs early this year, paving the way for the approval of biogenerics - and a potential goldmine for the generics companies.
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
Pharmaceutical Executive October 1, 2010	Euro Soul-Searching on Competition A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers.
Pharmaceutical Executive January 1, 2006 Sarah Houlton	Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice.
Chemistry World September 17, 2010 Andrew Turley	Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report.
Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
Managed Care December 2007	Insurers Lean Toward Generic Alternatives More insurers are focusing their attention on a second approach to generic drug management -- generic alternatives, which contain different active ingredients, but have comparable efficacy to brand-name drugs in the same class.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
Pharmaceutical Executive May 1, 2011 Stan Bernard	Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf.
Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
Chemistry World October 23, 2009 Matt Wilkinson	What's in a pill? Buying cheap drugs over the internet is well known to be a risky business. But the sinister menace of the 'falsified' active pharmaceutical ingredient gets far less publicity.
Pharmaceutical Executive September 1, 2012 Jill Wechsler	Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Chemistry World October 10, 2012 Maria Burke	Illegal medicines seized in worldwide operation During the nine-day operation, coordinated by INTERPOL and involving 100 countries, around 18,000 illegal online pharmacy websites were shut down and 79 people were arrested.
Chemistry World March 17, 2014 Phillip Broadwith	UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April.
Managed Care November 2005	Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.
Pharmaceutical Executive September 1, 2006 Reznick & Kobak	Legal: Authorized Generics: Still Legal--and Holding Despite the rattle and hum, courts continue to support the practice of authorized generics. The response? Generic manufacturers are changing the way they argue these cases.
The Motley Fool May 9, 2006 Stephen D. Simpson	Will Par Stay in the Fairway? Par Pharmaceutical is relatively unloved; does that mean opportunity or inferiority for investors?
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
Managed Care March 2008 John Carroll	Should Plans Pay Physicians To Switch Patients to Generics? The AMA calls it a kickback, but the industry sees it as just good practice to give doctors an incentive to get patients on equivalent generics
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
The Motley Fool November 6, 2006 Brian Lawler	The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note.